Zobrazeno 1 - 10
of 310
pro vyhledávání: '"Pedro Pérez‐Segura"'
Autor:
María del Mar Noblejas-López, Elena García-Gil, Pedro Pérez-Segura, Atanasio Pandiella, Balázs Győrffy, Alberto Ocaña
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Regulatory T cells (Tregs) is a subtype of CD4+ T cells that produce an inhibitory action against effector cells. In the present work we interrogated genomic datasets to explore the transcriptomic profile of breast tumors with high expressio
Externí odkaz:
https://doaj.org/article/74224a059ba148d49dfab9e6ca39f072
Autor:
Silvia Sánchez-Ramón, MD, PhD, Jesús Fuentes-Antrás, MD, Nicholas L. Rider, MD, Pedro Pérez-Segura, MD, PhD, Eduardo de la Fuente-Muñoz, MD, Miguel Fernández-Arquero, PhD, Esmeralda Neves, MD, Rebeca Pérez de Diego, PhD, Alberto Ocaña, MD, PhD, Kissy Guevara-Hoyer, MD, PhD
Publikováno v:
Journal of Allergy and Clinical Immunology: Global, Vol 3, Iss 2, Pp 100203- (2024)
Background: Gastric cancer (GC) stands as a prominent cause of cancer-related mortality and ranks second among the most frequently diagnosed malignancies in individuals with common variable immunodeficiency (CVID). Objective: We sought to conduct a c
Externí odkaz:
https://doaj.org/article/999d1c18df1e4ce0b69c419d841eeff7
Autor:
Alfonso López de Sá, Cristina Díaz-Tejeiro, Elisa Poyatos-Racionero, Cristina Nieto-Jiménez, Lucía Paniagua-Herranz, Adrián Sanvicente, Emiliano Calvo, Pedro Pérez-Segura, Víctor Moreno, Francisco Moris, Alberto Ocana
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-13 (2023)
Abstract Antibody–drug conjugates (ADCs) have emerged as a novel therapeutic strategy that has successfully reached patient treatment in different clinical scenarios. ADCs are formed by an antibody against a specific tumor-associated antigen (TAA),
Externí odkaz:
https://doaj.org/article/c72087b5dfa54ed0aa029fccbd8b25e2
Autor:
Adrián Sanvicente García, Manuel Pedregal, Lucía Paniagua-Herranz, Cristina Díaz-Tejeiro, Cristina Nieto-Jiménez, Pedro Pérez Segura, Gyöngyi Munkácsy, Balázs Győrffy, Emiliano Calvo, Víctor Moreno, Alberto Ocaña
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 10, p 5345 (2024)
The identification of targets that are expressed on the cell membrane is a main goal in cancer research. The Lymphocyte Antigen 6 Family Member G6D (LY6G6D) gene codes for a protein that is mainly present on the surface of colorectal cancer (CRC) cel
Externí odkaz:
https://doaj.org/article/12a3623042cd4919b4effc47d41c292d
Autor:
Elena González-Guerra, Alberto Conde Taboada, José Antonio Cortés Toro, Eduardo López Bran, Pedro Pérez Segura
Publikováno v:
Anais Brasileiros de Dermatologia, Vol 98, Iss 5, Pp 696-698 (2023)
Externí odkaz:
https://doaj.org/article/ab959f2f235b4e9a99efad44d74f203b
Autor:
Esther Cabañas Morafraile, Cristina Saiz-Ladera, Cristina Nieto-Jiménez, Balázs Győrffy, Adam Nagy, Guillermo Velasco, Pedro Pérez-Segura, Alberto Ocaña
Publikováno v:
Current Oncology, Vol 30, Iss 3, Pp 2569-2581 (2023)
Despite the impressive results obtained with immunotherapy in several cancer types, a significant fraction of patients remains unresponsive to these treatments. In colorectal cancer (CRC), B-RafV600 mutations have been identified in 8–15% of the pa
Externí odkaz:
https://doaj.org/article/e41c2709dfde49eaa725839de2ad6b27
Autor:
Adrián Sanvicente, Cristina Díaz-Tejeiro, Cristina Nieto-Jiménez, Lucia Paniagua-Herranz, Igor López Cade, Győrffy Balázs, Víctor Moreno, Pedro Pérez-Segura, Emiliano Calvo, Alberto Ocaña
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 7, p 3987 (2024)
Immuno-oncology has gained momentum with the approval of antibodies with clinical activities in different indications. Unfortunately, for anti-PD (L)1 agents in monotherapy, only half of the treated population achieves a clinical response. For other
Externí odkaz:
https://doaj.org/article/6cdddf10de4345e7aa95611bb8650b3a
Autor:
Lucía Paniagua-Herranz, Irene Moreno, Cristina Nieto-Jiménez, Esther Garcia-Lorenzo, Cristina Díaz-Tejeiro, Adrián Sanvicente, Bernard Doger, Manuel Pedregal, Jorge Ramón, Jorge Bartolomé, Arancha Manzano, Balázs Gyorffy, Álvaro Gutierrez-Uzquiza, Pedro Pérez Segura, Emiliano Calvo, Víctor Moreno, Alberto Ocana
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 4, p 2222 (2024)
The identification of surfaceome proteins is a main goal in cancer research to design antibody-based therapeutic strategies. T cell engagers based on KLK2, a kallikrein specifically expressed in prostate cancer (PRAD), are currently in early clinical
Externí odkaz:
https://doaj.org/article/c3b8403f9c0744b0baf28b3578bf3380
Autor:
Cristina Nieto‐Jiménez, Adrián Sanvicente, Cristina Díaz‐Tejeiro, Víctor Moreno, Alfonso lopez deSá, Emiliano Calvo, Joaquín Martínez‐López, Pedro Pérez‐Segura, Alberto Ocaña
Publikováno v:
Clinical and Translational Medicine, Vol 13, Iss 9, Pp n/a-n/a (2023)
Abstract Introduction Antibody‐drug conjugates (ADCs) are a family of therapeutic agents that have demonstrated clinical activity in several indications. Material and methods In this article, we performed a deep analysis of their clinical landscape
Externí odkaz:
https://doaj.org/article/445511a833964204a594eaf0a23f9c5e
Autor:
Jordi Rubió-Casadevall, Beatriz Cirauqui Cirauqui, Javier Martinez Trufero, Maria Plana Serrahima, Almudena García Castaño, Alberto Carral Maseda, Lara Iglesias Docampo, Pedro Pérez Segura, Isaac Ceballos Lenza, Vanesa Gutiérrez Calderón, José Fuster Salvà, Carolina Pena Álvarez, Irene Hernandez, Edel del Barco Morillo, Manuel Chaves Conde, Joaquina Martínez Galán, Marisa Durán Sánchez, Vanesa Quiroga, Eugenia Ortega, Ricard Mesia
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectivesThe aim of this study was to confirm the efficacy of the ERBITAX scheme (paclitaxel 80 mg/m2 weekly and cetuximab 400 mg/m2 loading dose, and then 250 mg/m2 weekly) as first-line treatment for patients with recurrent/metastatic squamous cel
Externí odkaz:
https://doaj.org/article/2c2ce3b877f44930902325a31aadefe0